Bafna Pharmaceuticals (BOM:532989) Cyclically Adjusted Revenue per Share: ₹ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532989 Bafna Pharmaceuticals Ltd BOM:532989
58 GF Score
Price ₹322.50
GF Value ₹87.67
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Cyclically Adjusted Revenue per Share?

Bafna Pharmaceuticals BOM:532989 +1.99% 58 Cyclically Adjusted Revenue per Share is ₹ as of Jun. 2026. GuruFocus rates BOM:532989 with a GF Score™ of 58/100 and a GF Value™ of ₹87.67 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bafna Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹11.237. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bafna Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-21), Bafna Pharmaceuticals's current stock price is ₹322.50. Bafna Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was . Bafna Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bafna Pharmaceuticals was 4.81. The lowest was 1.15. And the median was 1.72.


Bafna Pharmaceuticals  (BOM:532989) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bafna Pharmaceuticals was 4.81. The lowest was 1.15. And the median was 1.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bafna Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Bafna Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bafna Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BOM:532989 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:532989
58GF Score
Bafna Pharmaceuticals Ltd BOM:532989
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bafna Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.237/167.3573*167.3573
=11.237

Current CPI (Jun. 2026) = 167.3573.

Bafna Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 16.934 70.768 40.047
201106 18.091 72.298 41.877
201109 20.337 75.359 45.165
201112 12.053 75.359 26.767
201203 21.140 76.889 46.014
201303 85.687 0.000
201403 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201906 2.895 120.880 4.008
201909 4.889 123.175 6.643
201912 46.183 126.235 61.227
202003 55.515 124.705 74.502
202006 70.605 127.000 93.041
202009 6.425 130.118 8.264
202012 7.387 130.889 9.445
202103 9.232 131.771 11.725
202106 8.986 134.084 11.216
202109 12.022 135.847 14.811
202112 8.649 138.161 10.477
202203 6.333 138.822 7.635
202206 7.155 142.347 8.412
202209 9.283 144.661 10.739
202212 14.465 145.763 16.608
202303 17.857 146.865 20.349
202306 17.732 150.280 19.747
202309 17.195 151.492 18.996
202312 12.023 152.924 13.158
202403 17.500 153.035 19.138
202406 14.071 155.789 15.116
202409 17.045 157.882 18.068
202412 14.029 158.323 14.830
202503 16.512 157.552 17.540
202506 14.636 159.755 15.332
202509 14.993 162.289 15.461
202512 16.184 163.281 16.588
202603 17.855 164.272 18.190
202606 11.237 167.357 11.237

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹ mean?
Bafna Pharmaceuticals (BOM:532989) has a Cyclically Adjusted Revenue per Share of ₹ as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Bafna Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹. Overall, Bafna Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Bafna Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (BOM:532989) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹87.67, compared to a current price of ₹322.50 — trading 267.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹. Bafna Pharmaceuticals' overall GF Score™ is 58/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bafna Pharmaceuticals (BOM:532989), the current Cyclically Adjusted Revenue per Share is ₹ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (BOM:532989) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹322.50 is trading 267.9% above its estimated GF Value™ of ₹87.67. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:532989:

  • Cyclically Adjusted Revenue per Share:
  • GF Value™: ₹87.67 vs. price of ₹322.50 (267.9% above fair value)
  • GF Score™: 58/100 with 9 warning signs

No single metric tells the full story. See the BOM:532989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges BAFNAPH:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
58GF Score

Get the complete analysis for BOM:532989

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹322.50
Price
₹87.67
GF Value